Dosing & Uses
Dosage Forms & Strengths
powder for injection
- Plts <50x10³/mcL, increase dose by 1 mcg/kg qWeek
- Plts >200 x 10³/mcL for 2 consecutive weeks, reduce dose by 1 mcg/kg qWeek
- Plts >400 x 10³/mcL, do not dose; resume at dose reduced by 1 mcg/kg once Plt <200 x 10³/mcL
- Monitor: CBC and platelets prior to, during, and for 2 weeks post-last dose
- No more than 10 mcg/kg/week
- Discontinue if no clinically significant improvement after 4 weeks at 10 mcg/kg dose
Not for self-administration
Reconstitute Single-use Vial Containing
- 250 mcg deliverable drug (total content 375 mcg) in 0.72 mL sterile water for injection yields 250 mcg/0.5 mL deliverable amount
- 500 mcg deliverable drug (total content 625 mcg) in 1.2 mL sterile water for injection yields 500 mcg/mL deliverable amount
- Do NOT use bacteriostatic water for injection for reconstitution
- Gently swirl and invert to dissolve
- Reconstituted solution may be stored protected from light for 24 hr at room temperature or refridgerated
Other Indications & Uses
- Chronic immune thrombocytopenic purpura after insufficient response to corticosteroids, IVIG or splenectomy
- Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts
<18 years: Safety and efficacy not established
Upper respiratory infection (17%)
Pain in extremity (13%)
Back pain (13%)
Abdominal pain (11%)
Within 24 hr of receiving myelosuppressive chemotherapy or radiation therapy
>10% leukemic myeloid blasts in bone marrow or peripheral blood
Thrombotic/thromboembolic complications may result from increases in platelet counts with therapy; portal vein thrombosis reported in patients with chronic liver disease receiving therapy
Thrombocytopenia may worsen after discontinuation; if severe thrombocytopenia develops during therapy, assess patients for the formation of neutralizing antibodies
In some patients with myelodysplastic syndrome, therapy increases blast cell counts and increases risk of progression to acute myelogenous leukemia
Not indicated for non-ITP thrombocytopenia
Caution in pre-existing heart failure, history of fluid retention, hepatic or renal impairment
Dyspnea may occur
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Discontinue drug or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Fusion antibody-peptide that is a thrombopoietin receptor agonist; stimulates proliferation, differentiation, and activity of monocytes, neutrophils, eoxinophils, and macrophages
Peak plasma time: 1-3 hr (SC)
Onset: 7-14 days (increase in WBC)
Half-life elimination: 60 min (IV); 2.7 hr (SC)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs